Related Experiment Video
Updated: May 17, 2026
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Gastrointestinal stromal tumours: Our experience
Prashant Kumar1, Amit Agrawal, A K Shah
1Department of Surgery, Armed Forces Medical College, Pune, India.
The Indian Journal of Surgery
|November 8, 2012
Summary
Gastrointestinal stromal tumors (GIST) are rare GI sarcomas. This study highlights varied presentations and emphasizes accurate imaging, individualized management, and immunohistochemistry for optimal treatment with imatinib mesylate for high-risk cases.
Area of Science:
- Gastroenterology
- Surgical Oncology
- Pathology
Background:
- Gastrointestinal stromal tumors (GIST) are heterogeneous mesenchymal neoplasms of the gastrointestinal tract (GIT).
- GIST constitute a small fraction (0.2%) of all gastrointestinal tumors.
- Surgery remains the primary treatment for resectable, non-metastatic GIST, despite advances in chemotherapy.
Purpose of the Study:
- To report the management experience of GIST, the most common sarcomas found in the GIT.
- To analyze the clinical presentation and treatment outcomes of GIST cases.
Main Methods:
- A retrospective review of all GIST cases managed between April 2006 and June 2008.
- Inclusion of all patients diagnosed with and treated for GIST during the study period.
- Utilized diagnostic imaging including Ultrasound (USG) and Computed CECT scans for tumor delineation.
Main Results:
- Thirteen GIST cases were surgically managed; common symptoms included abdominal lump and pain.
- Tumors originated predominantly from the small bowel (7/13) and stomach (4/13).
- Resection and anastomosis were performed in 12 cases; 2 patients received postoperative chemotherapy, and immunohistochemistry was performed in 4 cases.
Conclusions:
- GIST presents with diverse clinical manifestations requiring accurate diagnosis via CECT.
- Individualized treatment strategies are crucial, incorporating immunohistochemistry for risk stratification.
- Imatinib mesylate is indicated for high-risk, metastatic, or unresectable GIST, particularly in CD117-positive patients. Six-monthly follow-up with imaging is recommended.
